Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $50 price target.
B. Riley Securities analyst Sahil Kazmi maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $29 to $50.
Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $30 to $45.
Harrow (NASDAQ:HROW) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.20) by 70 ...
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has ...
Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $26 to $30.
